Anida Pharma LLC, based in Cambridge, MA, is a pioneering biopharmaceutical company that is revolutionizing the treatment of eye diseases by developing first-in-class therapies. By harnessing the body's own protective mechanisms, Anida aims to prevent and slow the progression of ocular diseases, ultimately preserving vision and improving patients' quality of life.
With a deep understanding of the endogenous protective mechanisms of the eye, Anida has created AP-001, a modified version of neuroprotectin D1 (NPD1), a natural compound found in the eye. AP-001, administered as an eye drop, effectively distributes within ocular tissues, providing excellent tolerability and targeting both corneal and retinal progressive diseases. Through their commitment to efficacy, safety, and ease-of-use, Anida Pharma is at the forefront of innovative solutions for eye health.
Generated from the website